Source link : https://newshealth.biz/health-news/can-monthly-dosing-with-novel-glp-1-maintain-weight-loss/
At the American Diabetes Association annual meeting, updated phase II data from the VESPER program showed that patients who achieved weight loss with a weekly dose of the ultra-long-acting investigational GLP-1 agonist berobenatide could transition to monthly dosing and maintain that trajectory with favorable gastrointestinal (GI) tolerability. In this MedPage Today video, John Buse, MD, […]
The post Can Monthly Dosing With Novel GLP-1 Maintain Weight Loss? first appeared on News Health.
—-
Author : News Health
Publish date : 2026-06-22 16:00:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8